<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------
SCHEDULE 13D
(RULE 13d-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934/1/
CELLEGY PHARMACEUTICALS, INC.
-----------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
15115 L 103
-----------
(CUSIP Number)
Hope Flack
BVF Partners L.P.
333 West Wacker Drive, Suite 1600
Chicago, Illinois 60606
(312) 263-7777
--------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 29, 1997
-------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
(Continued on following pages)
(Page 1 of 8 Pages)
- ---------------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 2 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
BIOTECHNOLOGY VALUE FUND, L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X] (b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 WC
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
5 REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
NUMBER 7 -0-
OF -----------------------------------------------------------
SHARED VOTING POWER
SHARES 8 313,560
BENEFICIALLY -----------------------------------------------------------
SOLE DISPOSITIVE POWER
OWNED BY 9 -0-
REPORTING -----------------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10 313,560
WITH
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
11 REPORTING PERSON
313,560
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES
12 CERTAIN SHARES* [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13 4.2%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 3 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
BVF PARTNERS L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X] (b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 OO
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
5 REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
NUMBER 7 -0-
OF -----------------------------------------------------------
SHARED VOTING POWER
SHARES 8 490,560
BENEFICIALLY -----------------------------------------------------------
SOLE DISPOSITIVE POWER
OWNED BY 9 -0-
REPORTING -----------------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10 490,560
WITH
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
11 REPORTING PERSON
490,560
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES
12 CERTAIN SHARES* [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13 6.6%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 4 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
BVF INC.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X] (b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 WC, OO
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
5 REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
NUMBER 7 -0-
OF -----------------------------------------------------------
SHARED VOTING POWER
SHARES 8 490,560
BENEFICIALLY -----------------------------------------------------------
SOLE DISPOSITIVE POWER
OWNED BY 9 -0-
REPORTING -----------------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10 490,560
WITH
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
11 REPORTING PERSON
490,560
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES
12 CERTAIN SHARES* [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13 6.6%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 IA,CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 5 OF 8 PAGES
- ----------------------- ---------------------
ITEM 1. SECURITY AND ISSUER.
This Statement on Schedule 13D (this "Statement") relates to the Common
Stock, no par value (the "Stock"), of Cellegy Pharmaceuticals, Inc., a
California corporation ("Cellegy"). The principal executive office of Cellegy is
located at 1065 East Hillsdale Boulevard, Suite 418, Foster City, California
94404.
ITEM 2. IDENTITY AND BACKGROUND.
The persons filing this Statement, the persons enumerated in Instruction C
of Schedule 13D and, where applicable, their respective places of organization,
general partners, directors, executive officers and controlling persons, and
certain information regarding each of them, are as follows:
(a) Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"),
BVF Partners L.P., a Delaware limited partnership ("Partners"), BVF Inc., a
Delaware corporation ("BVF Inc."), and Mark N. Lampert, an individual
("Lampert") (collectively, the "Reporting Persons").
(b) The business address of BVF and Partners is 333 West Wacker Drive,
Suite 1600, Chicago, Illinois 60606. The business address of BVF Inc. and
Lampert is One Sansome Street, 39th Floor, San Francisco, California 94104.
(c) Partners is the general partner of BVF, which is an investment limited
partnership. BVF Inc. is an investment adviser to and general partner of
Partners. Lampert is the sole shareholder, sole director and an officer of BVF
Inc.
(d) During the last five years, none of such persons has been convicted in
a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e) During the last five years, none of such persons was a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as
a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with
respect to such laws.
(f) Lampert is a citizen of the United States of America.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 6 OF 8 PAGES
- ----------------------- ---------------------
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Since July 3, 1997, Partners, in its capacity as general partner of BVF,
has purchased on behalf of such limited partnership an aggregate number of
313,560 shares of the Stock for an aggregate consideration of $744,705,
utilizing funds provided by BVF from its working capital pursuant to the terms
of its limited partnership agreement with Partners. In addition, Partners, in
its capacity as investment manager with respect to certain managed accounts, has
purchased on behalf of such managed accounts an aggregate number of 177,000
shares of the Stock for an aggregate consideration of $420,375, utilizing funds
under management by Partners pursuant to investment manager agreements between
Partners and such managed accounts.
ITEM 4. PURPOSE OF TRANSACTIONS.
The sole purpose of the acquisitions of the Stock reported herein is and
was for investment. The Reporting Persons did not at the time of such
acquisitions of the Stock, and do not presently, have any plan to acquire
control of Cellegy. The Reporting Persons may acquire or dispose of additional
shares of the Stock from time to time.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) BVF beneficially owns 313,560 shares of the Stock, Partners
beneficially owns 490,560 shares of the Stock, and BVF Inc. beneficially owns
490,560 shares of the Stock, approximately 4.2%, 6.6% and 6.6%, respectively, of
the aggregate number of shares outstanding as of July 29, 1997.
(b) BVF shares voting and dispositive power over the 313,560 shares of the
Stock it beneficially owns with Partners. Partners and BVF Inc. share voting
and dispositive power over the 490,560 shares of the Stock they beneficially own
with, in addition to BVF, the managed accounts on whose behalf Partners, as
investment manager, purchased such shares. The managed accounts on whose behalf
Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited
liability company ("ILL10") and Biotechnology Value Fund, Ltd., a Cayman Islands
Corporation ("BVF Ltd."). ILL10 and BVF Ltd. are collectively referred to
herein as the "Accounts." The Accounts specialize in holding biotechnology
stocks for investment purposes and the business address of each is % BVF
Partners L.P., 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606.
(c) Exhibit B attached hereto contains information as to all transactions
in the Stock by the Reporting Persons during the past 60 days. The Reporting
Persons purchased an aggregate of 190,560 shares of the Stock on July 3, 1996,
paying cash in open market, over-the-counter transactions. On July 29, 1997, the
Reporting Persons purchased 300,000 shares of the Stock directly from Cellegy,
paying
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 7 OF 8 PAGES
- ----------------------- ---------------------
cash. No other transactions in the Stock have been effected by the Reporting
Persons during the past 60 days.
(d) The Accounts are entitled to receive dividends and any sale proceeds
with respect to the Stock in proportion to their respective ownership interests
therein.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Partners is the general partner of BVF pursuant to a limited partnership
agreement which authorizes Partners, among other things, to invest the funds of
BVF in the Stock and to vote and dispose of the Stock. Pursuant to such
limited partnership agreement, Partners is entitled to allocations based on
assets under management and realized and unrealized gains thereon. Pursuant to
investment management agreements with the Accounts, Partners and BVF Inc. have
the authority, among other things, to invest funds of the Accounts in the Stock
and to vote and dispose of the Stock. Pursuant to such agreements, Partners and
BVF Inc. receive fees based on assets under management and realized and
unrealized gains thereon. BVF Inc. is the general partner of Partners and may be
deemed to own beneficially securities over which Partners exercises voting and
dispositive power.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit A - Agreement Regarding Joint Filing
Exhibit B - Transactions in the Stock by the Reporting Persons during the
past 60 days.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 15115 L 103 13D PAGE 8 OF 8 PAGES
- ----------------------- ---------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: August 29, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
-----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
-------------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
--------------------------------
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the statement
containing the information required by Schedule 13D, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them. The undersigned
further agree that any amendments or supplements thereto shall also be filed on
behalf of each of them.
Dated: August 29, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
-----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
-------------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT B
TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
--------------------------------------------------
DURING THE PAST 60 DAYS
-----------------------
<TABLE>
<CAPTION>
Settlement For the Price per
Date By Account of Quantity Share Type of Trade Broker
- ---------- ----------- ---------- -------- --------- ------------- ------
<C> <S> <C> <C> <C> <C> <C>
07/03/97 Partners BVF 113,560 $2.3750 Purchase FBCO
- --------------------------------------------------------------------------------------
07/03/97 Partners ILL10 17,000 $2.3750 Purchase FBCO
- --------------------------------------------------------------------------------------
07/03/97 Partners BVF Ltd. 60,000 $2.3750 Purchase FBCO
- --------------------------------------------------------------------------------------
07/29/97 Partners BVF 200,000 $2.3750 Purchase NB
- --------------------------------------------------------------------------------------
07/29/97 Partners BVF Ltd. 100,000 $2.3750 Purchase NB
- --------------------------------------------------------------------------------------
</TABLE>
FBCO = First Boston
NB = No Broker
